Nanoparticulate delivery and targeting of RNA to the brain

Area of Science:

• Neuroscience
• Biotechnology
• Oncology

Background:

• The blood-brain barrier (BBB) significantly hinders treatment of central nervous system (CNS) disorders, especially aggressive brain cancers (glioblastoma, medulloblastoma).
• RNA and CRISPR gene therapies offer potential for targeting previously undruggable pathways in brain cancers.
• Current clinical successes of RNA therapies are primarily in non-CNS diseases, highlighting the need for CNS-specific advancements.

Purpose of the Study:

• To review strategies for delivering RNA-based therapies across the BBB for brain cancer treatment.
• To summarize recent clinical advancements and challenges in utilizing nanoparticles for CNS RNA delivery.
• To emphasize the need for interdisciplinary collaboration in nanoparticle engineering, immune evasion, and non-invasive delivery for brain applications.

Main Methods:

• Review of current literature on nanoparticle (NP) delivery systems for RNA therapies in the CNS.
• Analysis of targeting strategies (e.g., GLUT1, RVG peptide, ApoE mimetic peptide) for enhanced BBB penetration.
• Evaluation of non-invasive delivery techniques, such as focused ultrasound, for improving RNA transport.

Main Results:

• Nanoparticles (NPs), particularly lipid nanoparticles (LNPs) and viral vectors, are essential for advancing RNA therapies in brain cancer.
• Targeting moieties and non-invasive delivery methods show promise in overcoming BBB limitations.
• Recent clinical efforts are exploring various RNA delivery approaches for brain tumors.

Conclusions:

• Overcoming the BBB remains a primary obstacle for effective RNA and CRISPR gene therapy in brain cancers.
• Continued innovation in NP design, targeting ligands, and non-invasive delivery is critical for clinical translation.
• Interdisciplinary research is vital to engineer NPs for immune evasion and efficient CNS delivery of RNA therapeutics.